Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EYE National Vision	$23.17 +0.5%	$18.48	$9.56 ▼ $23.42	$1.83B	1.24	1.92 million shs	1.99 million shs
IRTC iRhythm Technologies	$154.71 +1.3%	$136.39	$55.92 ▼ $154.93	$4.94B	1.4	482,705 shs	548,723 shs
PRCT PROCEPT BioRobotics	$56.91 -2.9%	$57.50	$47.04 ▼ $103.81	$3.15B	1.1	841,031 shs	1.86 million shs
SLNO Soleno Therapeutics	$83.25 -0.9%	$76.59	$39.41 ▼ $86.67	$4.20B	-2.69	786,713 shs	3.28 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EYE National Vision	0.00%	+1.27%	+16.14%	+80.73%	+84.03%
IRTC iRhythm Technologies	0.00%	+6.15%	+8.77%	+47.34%	+50.42%
PRCT PROCEPT BioRobotics	0.00%	-5.50%	+2.15%	-5.23%	-2.03%
SLNO Soleno Therapeutics	0.00%	+4.09%	+10.09%	+15.64%	+110.44%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
EYE National Vision	2.5225 of 5 stars	2.2	2.0	3.3	2.1	0.8	0.0
IRTC iRhythm Technologies	1.0171 of 5 stars	2.5	1.0	0.0	2.0	0.8	0.6
PRCT PROCEPT BioRobotics	2.5096 of 5 stars	3.4	1.0	0.0	3.0	2.5	0.6
SLNO Soleno Therapeutics	4.6534 of 5 stars	4.5	2.0	4.6	2.1	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
EYE National Vision	2.44	Hold	$18.67	-19.44% Downside
IRTC iRhythm Technologies	2.90	Moderate Buy	$138.60	-10.41% Downside
PRCT PROCEPT BioRobotics	2.86	Moderate Buy	$90.00	58.14% Upside
SLNO Soleno Therapeutics	3.09	Buy	$107.10	28.65% Upside

Current Analyst Ratings Breakdown

Latest EYE, SLNO, IRTC, and PRCT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/23/2025	SLNO Soleno Therapeutics	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
6/23/2025	SLNO Soleno Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$110.00
6/18/2025	EYE National Vision	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$22.00 ➝ $26.00
6/11/2025	IRTC iRhythm Technologies	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$130.00 ➝ $160.00
5/22/2025	IRTC iRhythm Technologies	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$130.00 ➝ $167.00
5/19/2025	EYE National Vision	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Market Perform ➝ Market Perform	$13.00 ➝ $19.00
5/12/2025	EYE National Vision	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$14.00 ➝ $17.00
5/9/2025	EYE National Vision	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$13.00 ➝ $17.00
5/9/2025	EYE National Vision	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$13.00 ➝ $21.00
5/8/2025	EYE National Vision	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$18.00 ➝ $20.00
5/8/2025	EYE National Vision	Loop Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$18.00 ➝ $20.00

(Data available from 6/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EYE National Vision	$1.82B	1.00	$1.64 per share	14.16	$10.37 per share	2.23
IRTC iRhythm Technologies	$591.84M	8.34	N/A	N/A	$2.90 per share	53.35
PRCT PROCEPT BioRobotics	$224.50M	14.03	N/A	N/A	$7.71 per share	7.38
SLNO Soleno Therapeutics	N/A	N/A	N/A	N/A	$5.68 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EYE National Vision	-$28.50M	-$0.33	N/A	85.81	3.40	-1.40%	3.44%	1.40%	8/6/2025 (Estimated)
IRTC iRhythm Technologies	-$113.29M	-$3.14	N/A	N/A	N/A	-15.90%	-101.04%	-9.55%	7/30/2025 (Estimated)
PRCT PROCEPT BioRobotics	-$91.41M	-$1.70	N/A	N/A	N/A	-36.20%	-28.09%	-20.02%	7/30/2025 (Estimated)
SLNO Soleno Therapeutics	-$175.85M	-$4.62	N/A	N/A	N/A	N/A	-77.52%	-63.44%	8/6/2025 (Estimated)

Latest EYE, SLNO, IRTC, and PRCT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/7/2025	Q1 2025	EYE National Vision	$0.32	$0.34	+$0.02	$0.18	$510.30 million	$510.32 million
5/7/2025	Q1 2025	SLNO Soleno Therapeutics	-$1.14	-$0.95	+$0.19	-$0.95	N/A	N/A
5/1/2025	Q1 2025	IRTC iRhythm Technologies	-$0.89	-$0.95	-$0.06	-$0.97	$153.39 million	$158.68 million
4/24/2025	Q1 2025	PRCT PROCEPT BioRobotics	-$0.49	-$0.45	+$0.04	-$0.45	$65.39 million	$69.16 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
EYE National Vision	N/A	N/A	N/A	N/A	N/A
IRTC iRhythm Technologies	N/A	N/A	N/A	N/A	N/A
PRCT PROCEPT BioRobotics	N/A	N/A	N/A	N/A	N/A
SLNO Soleno Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EYE National Vision	0.29	0.54	0.35
IRTC iRhythm Technologies	7.47	5.71	5.58
PRCT PROCEPT BioRobotics	0.13	8.95	7.75
SLNO Soleno Therapeutics	0.21	19.64	19.64

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
EYE National Vision	N/A
IRTC iRhythm Technologies	N/A
PRCT PROCEPT BioRobotics	89.46%
SLNO Soleno Therapeutics	97.42%

Insider Ownership

Company	Insider Ownership
EYE National Vision	2.70%
IRTC iRhythm Technologies	1.10%
PRCT PROCEPT BioRobotics	6.60%
SLNO Soleno Therapeutics	6.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
EYE National Vision	13,411	79.05 million	76.92 million	Optionable
IRTC iRhythm Technologies	2,000	31.92 million	31.57 million	Optionable
PRCT PROCEPT BioRobotics	430	55.33 million	51.68 million	Optionable
SLNO Soleno Therapeutics	30	50.39 million	47.17 million	Optionable

EYE, SLNO, IRTC, and PRCT Headlines

Recent News About These Companies

Lisanti Capital Growth LLC Purchases Shares of 25,365 Soleno Therapeutics, Inc. (NASDAQ:SLNO)

June 29 at 6:33 AM | marketbeat.com

Soleno Therapeutics, Inc. (NASDAQ:SLNO) Insider Sells $22,410.50 in Stock

June 26 at 8:59 PM | marketbeat.com

SLNO Soleno Therapeutics, Inc. - Seeking Alpha

June 25, 2025 | seekingalpha.com

Soleno Therapeutics Highlights New Data on VYKAT(TM) XR at the 2025 United in Hope: International Prader-Willi Syndrome Conference

June 25, 2025 | santelog.comS

Soleno gains as Betaville cites buyout interest (update)

June 24, 2025 | msn.com

Soleno Therapeutics (NASDAQ:SLNO) Sets New 1-Year High - Here's What Happened

June 23, 2025 | marketbeat.com

Soleno Therapeutics initiated with a Buy at TD Cowen

June 23, 2025 | msn.com

FDA Approval for its Drug Lifted Soleno Therapeutics (SLNO) Shares by 60%

June 23, 2025 | msn.com

Soleno Therapeutics (NASDAQ:SLNO) Coverage Initiated at TD Cowen

June 23, 2025 | marketbeat.com

Soleno Therapeutics: Overbought On VYKAT Approval Enthusiasm

June 22, 2025 | seekingalpha.com

GAMMA Investing LLC Increases Position in Soleno Therapeutics, Inc. (NASDAQ:SLNO)

June 22, 2025 | marketbeat.com

Piper Sandler Reaffirms Overweight Rating on Soleno (SLNO) Driven by Strong VYKAT XR Prospects

June 20, 2025 | msn.com

Soleno Therapeutics to Present Research Findings at 2025 International Prader-Willi Syndrome Conference

June 20, 2025 | quiverquant.comQ

Soleno Therapeutics Announces Multiple Presentations at the 2025 United in Hope: International Prader-Willi Syndrome Conference

June 20, 2025 | globenewswire.com

Soleno Therapeutics, Inc. (NASDAQ:SLNO) Receives Consensus Rating of "Buy" from Brokerages

June 14, 2025 | marketbeat.com

434,514 Shares in Soleno Therapeutics, Inc. (NASDAQ:SLNO) Acquired by Assenagon Asset Management S.A.

June 13, 2025 | marketbeat.com

Soleno Therapeutics (NASDAQ:SLNO) Sets New 12-Month High - Here's What Happened

June 12, 2025 | marketbeat.com

These 24 Stocks Are Ripe for a Short Squeeze

June 12, 2025 | schaeffersresearch.com

Soleno Therapeutics, Inc. (NASDAQ:SLNO) Shares Acquired by Harbor Capital Advisors Inc.

June 11, 2025 | marketbeat.com

California State Teachers Retirement System Has $988,000 Stake in Soleno Therapeutics, Inc. (NASDAQ:SLNO)

June 11, 2025 | marketbeat.com

Cantor Fitzgerald Comments on SLNO FY2026 Earnings

June 10, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
Robinhood Director Sells Millions, But HOOD Stock Eyes Gains
By Gabriel Osorio-Mazilli | June 19, 2025
View Robinhood Director Sells Millions, But HOOD Stock Eyes Gains
CrowdStrike Eyes Breakout as Cyber Threats Boost Demand
By Chris Markoch | June 24, 2025
View CrowdStrike Eyes Breakout as Cyber Threats Boost Demand
Sarepta Drops 42% on Fatalities; Markets Eye Solid Biosciences
By Leo Miller | June 18, 2025
View Sarepta Drops 42% on Fatalities; Markets Eye Solid Biosciences
Skyworks Stock Down 16% in 2025, Poised for AI Edge Surge
By Chris Markoch | June 27, 2025
View Skyworks Stock Down 16% in 2025, Poised for AI Edge Surge

EYE, SLNO, IRTC, and PRCT Company Descriptions

National Vision NASDAQ:EYE

$23.17 +0.11 (+0.48%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$22.66 -0.51 (-2.18%)

As of 06/27/2025 05:59 PM Eastern

National Vision Holdings, Inc., through its subsidiaries, operates as an optical retailer in the United States. The company operates in two segments, Owned & Host and Legacy. It offers eyeglasses and contact lenses, and optical accessory products; provides eye exams through its America's Best, Eyeglass World, Vista Optical, Fred Meyer, and Vista Optical military, as well as Vision Center branded stores; and offers health maintenance organization and optometric services. National Vision Holdings, Inc. was founded in 1990 and is headquartered in Duluth, Georgia.

iRhythm Technologies NASDAQ:IRTC

$154.71 +2.02 (+1.32%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$161.22 +6.51 (+4.21%)

As of 06/27/2025 07:04 PM Eastern

iRhythm Technologies, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. It offers Zio services, an ambulatory monitoring solution, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. The company also provides the Zio Monitor System, a prescription-only, remote electrocardiogram (ECG) monitoring system that consists of a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days and the Zio ECG Utilization Software System, which supports the capture and analysis of ECG data recorded by the Zio Monitor patch at the end of the wear period, including specific arrhythmia events detected by the ZEUS System; the Zio XT System is the previous generation of the Zio Monitor System and is a prescription-only, remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and the Zio AT system, a prescription-only, remote ECG monitoring system that similarly consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days and the ZEUS System, but which also incorporates the Zio AT wireless gateway that provides connectivity between the Zio AT patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with Verily Life Sciences LLC and Verity Ireland Limited to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.

PROCEPT BioRobotics NASDAQ:PRCT

$56.91 -1.72 (-2.93%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$56.90 -0.01 (-0.03%)

As of 06/27/2025 07:32 PM Eastern

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). It also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.

Soleno Therapeutics NASDAQ:SLNO

$83.25 -0.77 (-0.92%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$83.24 -0.02 (-0.02%)

As of 06/27/2025 07:11 PM Eastern

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time